Protective Effect of Aqueous and Ethanolic Extracts of Portulaca Oleracea Against Cisplatin Induced Nephrotoxicity

Document Type: Original Article

Authors

1 Medical Toxicology Research Center and School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s)
Portulaca oleracea L. is a herbaceous weed from portulacaceae family. It can be found in many parts of the world. Modern pharmacological studies have demonstrated that P. oleracea have antioxidant effects. The protective effect of aqueous and ethanolic extract of P. oleracea against cisplatin-induced renal toxicity was studied in rats.
Materials and Methods
Single intraperitoneal injection of 4 mg/kg cisplatin was administrated to rats. After 5 days, blood urea nitrogen (BUN) and serum creatinine (Scr) concentration were determined. Effect of aqueous and ethanolic extracts, before and after cisplatin injection on BUN and Scr, as well as morphological renal damage, was evaluated.
Results
It was indicated that treatment with aqueous and ethanolic extracts of P. oleracea in the highest dose (0.8 and 2 g/ kg), 6 and 12 hr before cisplatin injection reduced BUN and Scr. Tubular necrotic damage was not observed either.
Conclusion
Results suggest that P. oleracea extract may protect against cisplatin-induced renal toxicity and might serve as a novel combination agent with cisplan to limit renal injury.

Keywords


1.Lim YY, Quah EPL. Antioxidant properties of different cultivars of Portulaca oleracea. Food Chem 2007; 103:734-740.

2.Brickell C. Encyclopedia of Gardening. London: Dorling Kindersley; 1992.

3.Chan K, Islam MW, Kamil M, Radhakrishnan R, Zakaria MNM, Habibullah M, et al. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. sativa (Haw.) Celak. J Ethnopharmacol 2000; 73:445-451.

4.Okwuasaba F, Ejika C, Parry O. Effects of extracts of Portulaca oleracea on skletal muscle in vitro. J Ethnopharmacol 1987; 27:55-63.

5.Radhakrishnan R,Zakaria MN, Islam MW, Chen HB, Kamil M, Chan K, et al. Neuropharmacological actions of Portulaca oleraceae L v. sativa (Hawk). J Ethnopharmacol 2001; 76:171-176.

6.Abas F, Lajis NH, Israf DA, Khozirah S, Kalsom YU. Antioxidant and nitric oxide inhibition activities of selected Malay traditional vegetables. Food Chem 2006; 95:566-573.

7.Cai Y, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci 2004; 74:2157-2184.

8.Simopoulos AP. Omega-3 fatty acids and antioxidants in edible wild plants. Biol Res 2004; 37:263-277.

9.Yen GC, Chen HY, Peng HH. Evaluation of the cytotoxicity, mutagenicity and antimutagenicity of emerging edible plants. Food Chem Toxicol 2001; 39:1045-1053.

10.Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 4:9-17.

11.Lee KW, Jeong JY, Lim BJ, Chang Y-K, Lee S-J, Na K-R, et al. Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 2009; 257:137-143.

12.Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003; 63:72-82.

13.Kuhlmann MK, Horsch E, Burkhardt G, Wagner M, Kohler H. Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin. Arch Toxicol 1998; 72:536-540.

14.Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998; 53:394-401.

15.McClatchey KD. Clinical Laboratory Medicine London Williams & Wilkins; 1994.

16.Hammersen F. Histology. Munich: Urban and Schwarzenberg;1985.

17.Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med 2005; 2:383-386.

18.Heidman HT, Gerkens JF, Jackson EK, Branch RA. Attenuation of cisplatin induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Arch Pharmacol 1985; 329:201-205.

19.Montine TJ, Borch RF. Role of endogenous sulfur containing nucleophiles in an in vitro model of cis- diamminedichloroplatinium-induced nephrotoxicity. Biochem Pharmacol 1990; 39:1751-1757.

20.Rao M, Rao MMJ. Protective effects of selenomethionine against cisplatin-induced renal toxcity in mice and rats. Pharm Pharmacol 1992; 50:687-691.

21.Maliakel DM, Kagiya TV, Nair CKK. Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and [alpha]-tocopherol. Exp Toxicol Pathol 2008; 60:521-527.

22.Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 1996; 11:55-62.

23.Chan K, Islam MW, Kamil M, Radhakrishnan R, Zakaria MN, Habibullah M, et al. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. J Ethnopharmacol 2000; 73:445-451.

24.Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, et al. Interleukin-10 inhibits ischemic and cisplatin- induced acute renal injury. Kidney Int 2001; 60:2118-2128.

25.Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110:835-842.